Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide for stabilization of kidney function in primary IgA nephropathy
ISRCTN47722295Phase 4Completed
- Sponsor
- Fundeni Clinical Institute
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of budesonide in IgA nephropathy (IgAN), sponsored by Fundeni Clinical Institute. Primary endpoints: Estimated glomerular filtration rate, Proteinuria and 2 more. Started Mar 2020; status: completed.
02
Drugs
budesonide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ISRCTN47722295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN47722295.